Potashnick Robert 4

4 · Envoy Medical, Inc. · Filed Feb 17, 2026

AI-generated summary of this filing

Updated Feb 17, 2026

Envoy Medical (COCH) Interim CFO Robert Potashnick Buys Shares

What Happened

Robert Potashnick, Interim Chief Financial Officer of Envoy Medical (COCH), reported purchases on 2026-02-12. He purchased 212,500 shares at $0.40 each for a cash outlay of $85,000. In addition, the filing shows acquisition of 127,500 and 212,500 shares as derivative securities at a $0.00 price (total 340,000 derivative shares) on the same date.
The $85,000 cash purchase is a straight buy; the derivative acquisitions are non-cash and reflect issuance or conversion of warrants/options or similar instruments (see footnotes below). Purchases are typically viewed as more informative than routine sales, but the filing does not state any motivation.

Key Details

Transaction date: February 12, 2026. Form 4 filed: February 17, 2026 (check filing for timeliness flag).
Cash purchase: 212,500 shares @ $0.40 = $85,000.
Derivative acquisitions: 127,500 shares and 212,500 shares @ $0.00 (listed as derivative / non-cash acquisitions).
Shares owned after transaction: Not specified in the information you provided (check the full Form 4 for post-transaction holdings).
Footnotes in the filing:
- F1: Options to purchase 3,750 shares vest 2/5/2027; 11,250 shares vest pro rata on the 5th of each month for 36 months thereafter.
- F2: Some securities exercisable only upon shareholder approval to issue Class A common stock underlying the warrants.
- F3: Series A-1 Warrants expire either two years from initial exercise or 30 days after the company announces submission of a Premarket Approval Application to the FDA for its Acclaim CI Device.
- F4: Series A-2 Warrants expire either five years from initial exercise or 30 days after the company announces FDA approval for its Acclaim CI Device.

Context

The filing shows both a straightforward open-market/private purchase (cash) and non-cash derivative acquisitions. Derivative entries generally reflect issuance, conversion, or similar transactions involving warrants/options; they are not necessarily immediate stock sales.
Form 4s are generally due within two business days of the transaction—this filing was dated Feb 17 for Feb 12 transactions; check the full filing for any late-filing designation ("L") and related explanations.
As always, these filings show transactions by insiders but do not explain intent or predict company performance.

Form 4

Period: 2026-02-12

Interim CFO

Transactions

Purchase
Class A Common Stock
2026-02-12$0.40/sh+212,500$85,000→ 212,500 total
Purchase
Warrant (right to buy)
[F2][F3]
2026-02-12+127,500→ 127,500 total
Exercise: $0.40→ Class A Common Stock (127,500 underlying)
Purchase
Warrant (right to buy)
[F2][F4]
2026-02-12+212,500→ 212,500 total
Exercise: $0.40→ Class A Common Stock (212,500 underlying)

Holdings

Stock Option (right to buy)
[F1]
Exercise: $0.53Exp: 2036-02-05→ Class A Common Stock (15,000 underlying)
15,000

Footnotes (4)

[F1]Options to purchase 3,750 shares vest on 2/5/2027, and 11,250 shares vest pro rata on the 5th of each month thereafter for 36 consecutive months.
[F2]Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.
[F3]The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.
[F4]The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.

Signature

/s/ Andrew Nick as Attorney-in-Fact for Robert Potashnick pursuant to Power of Attorney filed herewith.|2026-02-16

2 files